The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Walking the line: The fate of nanomaterials at biological barriers
Open accessAbstract
Biological systems have developed an efficient multi-tiered defense system to block foreign substances such as engineered nanomaterials (NMs) from causing damage. In a pathological scenario, the disease itself may also pose additional barriers due to the imbalance between abnormal cells and their surrounding microenvironment, and NMs could behave similarly or differently to classic foreign substances, depending on their unique characteristics. Thus, understanding the mechanisms that govern the fate of NMs against these biological barriers, including the strategies that can be used to shift their fate between access and blockage, become key information for NMs design. In this manuscript, we first describe the biological barriers that NMs may encounter, and further discuss how these biological barrier interactions could shift the fate of NMs between toxicity and therapeutic potential. A list of effects that may influence NMs access at nano/bio interface are presented and discussed, followed by personal insights on the important nano/bio topics that require additional research for a better understanding of NM/biological barrier interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · cited 1×
“Potential safety concerns regarding nanotherapeutics are growing as work to develop solutions to the problem of their nonspecific distribution is still ongoing [54, 55].”
BackgroundIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Although the EPR effect has been comprehensively reviewed [79-81], there is still continuous debate regarding the effectiveness of EPR effect, especially in the clinical setting.”
BackgroundIntestinal mucosal barrier function in health and disease
Turner, J. R. (2009) · Nature reviews. Immunology · doi:10.1038/nri2653 · Cited by 3,952 · cited 2×
“Minimally, it involves i) endocytosis through epithelial cells, ii) transcytosis via the M-cell rich layer of Peyer’s Patches, iii) persorption through gaps in the gut lumen, and iv) paracellular uptake under pathological conditions [20, 23].”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The defense system includes physiological barriers, such as skin [2], air-blood lung barrier [3], barriers in circulation [4, 5], blood-brain barrier [6], and barriers in the reproductive system [7], etc.”
BackgroundEffect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Stromal depletion molecules have been developed to essentially obliterate the dense stromal environment to improve drug delivery [86].”
BackgroundHyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Deposition and biokinetics of inhaled nanoparticles
Geiser, M., & Kreyling, W. G. (2010) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-7-2 · Cited by 747 · cited 1×
“It has been shown that the distribution of particles in the lungs is dependent on their physiochemical properties, most notably, size and charge [1, 29-31].”
BackgroundDiop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018892108 · Cited by 733
Transport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · cited 3×
“This tight influx control is complemented by the efflux transport system, which rapidly eliminates classic xenobiotics and NMs buildup in the brain, and together, these mechanisms protect the function of the central nervous system from external disruption [6].”
BackgroundNanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 1×
“While the BBB blockage is generally efficient, the exception indeed exists [34], and NMs are known to gain access across the BBB via a transcytosis-mediated route [35].”
BackgroundBanks, W. A., Jaspan, J. B., & Kastin, A. J. (1997) · Peptides · doi:10.1016/s0196-9781(97)00198-8 · Cited by 219
Evaluation of nanomedicines: stick to the basics
McNeil, S. E. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.73 · Cited by 126 · cited 3×
“For example, liposomal doxorubicin has low detectability in the tumor itself, but is still higher than the equivalent dose of free drug, and results in greater therapeutic outcomes because of its increased tumor exposure, PK and reduced cardiotoxicity [101].”
BackgroundInfluential
Cited by
Celebi Sozener, Z., Ozdel Ozturk, B., Cerci, P., Turk, M., Gorgulu Akin, B., Akdis, M., Altiner, S., Ozbey, U., Ogulur, I., Mitamura, Y., et al. (2022) · Allergy · doi:10.1111/all.15240 · Cited by 418
An overview of the use of nanozymes in antibacterial applications
Mei, L., Zhu, S., Liu, Y., Yin, W., Gu, Z., & Zhao, Y. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.129431 · Cited by 369
Self-citationNanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Wong, X. Y., Sena-Torralba, A., Álvarez-Diduk, R., Muthoosamy, K., & Merkoçi, A. (2020) · ACS Nano · doi:10.1021/acsnano.9b08133 · Cited by 363
Mazumdar, S., Chitkara, D., & Mittal, A. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.019 · Cited by 295
Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine
Ren, J., Andrikopoulos, N., Velonia, K., Tang, H., Cai, R., Ding, F., Ke, P. C., & Chen, C. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c02277 · Cited by 284
Self-citation
Metadata
- Authors
- Meng, H., Leong, W., Leong, K. W., Chen, C., & Zhao, Y.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 174
- Pages
- 41-53
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2800757159
- Cited by
- 186
- References
- 16
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.